Comparative Pharmacology
Head-to-head clinical analysis: DARIFENACIN versus DARIFENACIN HYDROBROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARIFENACIN versus DARIFENACIN HYDROBROMIDE.
DARIFENACIN vs DARIFENACIN HYDROBROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3 subtypes), reducing detrusor muscle contractility.
Darifenacin is a competitive muscarinic receptor antagonist, with high selectivity for the M3 receptor subtype, which mediates bladder contraction. By blocking M3 receptors in the detrusor muscle, it reduces bladder contractility and increases bladder capacity.
7.5 mg to 15 mg orally once daily
7.5 mg to 15 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 13-19 hours in young adults, increasing to about 17 hours in elderly; supports once-daily dosing.
Clinical Note
moderateDarifenacin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Darifenacin."
Clinical Note
moderateDarifenacin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Darifenacin."
Clinical Note
moderateDarifenacin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Darifenacin."
Clinical Note
moderateDarifenacin + Fluconazole
Terminal elimination half-life is approximately 13-19 hours; clinically, steady-state is reached within 3-5 days.
Approximately 60% of the dose is excreted renally (as metabolites, primarily 3-hydroxydarifenacin) and 40% fecally; less than 3% excreted unchanged.
Approximately 60% renal (as metabolites, <3% unchanged) and 40% fecal (primarily as metabolites).
Category C
Category C
Antimuscarinic
Antimuscarinic
"The metabolism of Fluconazole can be decreased when combined with Darifenacin."